This special series on Impact of Novel Neoadjuvant Treatment on Surgery Outcomes in Lung Cancer is co-edited by Dr. Dragana Jovanovic, from Internal Medicine Clinic "Akta Medica", Belgrade, Serbia; and Dr. Semra Bilaceroglu, from Izmir Dr. Suat Seren Training and Research Hospital for Thoracic Medicine and Surgery, Izmir, Turkey.
Thoracic Oncology and Palliative Medicine, Internal Medicine Clinic "Akta Medica", Belgrade, Serbia
Prof. Dragana Jovanovic is a Chest physician, subspecialist pulmonologist and subspecialist in Thoracic Oncology. Full Professor of Internal Medicine-Pulmonology and Thoracic Oncology, Prof. Jovanovic earned her medical degree from the University of Belgrade, School of Medicine, in pulmonology. She further completed an advanced fellowship in Pulmonology and subspecialization in (Thoracic) Oncology, at the same University. She has taken part in numerous research and educational projects, and also has been the organizer, scientific chair and the lecturers of numerous International Conferences, Educational Courses at School of Medicine. She has been the invited Guest Lecturer and/or Chair in numerous Conferences and Congresses, domestic and international.
Health Sciences University, Izmir Dr. Suat Seren Training and Research Hospital for Thoracic Medicine and Surgery, Izmir, Turkey
Prof. Semra Bilaceroglu works as an academic director in Izmir Dr. Suat Seren Training & Research Hospital for Thoracic Medicine & Surgery, University of Health Sciences, Turkey. She has been entitled “Visiting Professor” by the University of Belgrade School of Medicine. She is the past president of the European Association for Bronchology and Interventional Pulmonology (EABIP), an executive board member of the Turkish Respiratory Society and CHEST Global Governors, and is the EABIP-regent in the World Association for Bronchology and Interventional Pulmonology (WABIP) Board of Regents. She has published extensively in pulmonology and interventional pulmonology and is a reviewer and associate editor in several peer-reviewed international journals.
- Neoadjuvant chemotherapy with or without radiation – benefits and concerns
- Neoadjuvant immunotherapy as a novel treatment option for early stage non-small cell lung cancer
- Biomarkers under investigation for neoadjuvant immune checkpoint inhibitors in NSCLC
- Molecular targeted agents in neoadjuvant setting
- Imaging procedures in assessment of the response to neoadjuvant treatment in non-small cell lung cancer
- The role of bronchoscopy in preoperative re-staging in the era of novel neoadjuvant therapies
- Challenges for a thoracic surgeon after neoadjuvant treatment of non-small cell lung cancer
- Pathological response after neoadjuvant treatment
- 1Postoperative morbidity and mortality in patients treated with neoadjuvant therapy prior to surgery
The series “Impact of Novel Neoadjuvant Treatment on Surgery Outcomes in Lung Cancer” was commissioned by the editorial office, AME Surgical Journal without any sponsorship or funding. Dragana Jovanovic and Semra Bilaceroglu are serving as the unpaid Guest Editors for the series.